MedPath

Breast Implant-associated Anaplastic Large Cell Lymphoma (BIA-ALCL) Registry

Recruiting
Conditions
Anaplastic Large Cell Lymphoma Associated With Breast Implants (BIA-ALCL)
Registration Number
NCT04220970
Lead Sponsor
The Lymphoma Academic Research Organisation
Brief Summary

Anaplastic large cell lymphoma associated with breast implants (BIA-ALCL) is a rare disease seen only in women with a breast implant.

Because of the low incidence of this disease and the peculiar histological subtype, French authorities, in accordance with the recommendations of an expert group, recommended the implementation of a BIA-ALCL case registry, in connection with a national Multidisciplinary meeting (Réunion de Concertation Pluridisciplinaire nationale de recours- RCP).

This registry is opened in France and in Belgium

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
Female
Target Recruitment
150
Inclusion Criteria
  • Adult patients with an anaplastic large cell lymphoma associated with breast implants
Exclusion Criteria

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Overall response13 years
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (31)

A. Z. Sint-Jan Brugge-Oostende AV

🇧🇪

Bruges, Belgium

Clinique Universitaire Saint LUC

🇧🇪

Brussels, Belgium

Institut Jules Bordet

🇧🇪

Brussels, Belgium

Universitair Ziekenhuis Brussel

🇧🇪

Brussel, Belgium

Cliniques Universitaires de Bruxelles - Hôpital Erasme

🇧🇪

Bruxelles, Belgium

Universitair Ziekenhuis Antwerpen

🇧🇪

Edegem, Belgium

Universitair Ziekenhuis Gent

🇧🇪

Gent, Belgium

U.Z. Leuven - Campus Gasthuisberg

🇧🇪

Leuven, Belgium

CHU de Liège -Domaine Sart Tilman

🇧🇪

Liège, Belgium

CHU UCL Namur - Site Godinne

🇧🇪

Yvoir, Belgium

Scroll for more (21 remaining)
A. Z. Sint-Jan Brugge-Oostende AV
🇧🇪Bruges, Belgium
Sylvia SNAUWAERT, MD
Contact
+32 (0)50 45 23 28
sylvia.snauwaert@azsintjan.be

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.